Biolux Research, developer of OrthoPulse®, is pleased to announce the renewal of its partnership with the Schulman Study Group in an agreement to promote and provide innovative photobiomodulation products to Schulman orthodontic practices and patients.
The Schulman Study Group is a nationally recognised association of prominent orthodontic practices. Membership is extended exclusively by invitation to sustain the same high standard of practice performance and to provide access to new technology and opportunities for innovation and insight that orthodontists would not otherwise find. The Schulman Study Group members share a commitment to exceptional patient care, quality of orthodontic experience, and continuing education.
Previously, members of the Schulman Study Group participated in a beta evaluation of OrthoPulse®, Biolux’s flagship product for accelerating orthodontic treatment, in the US and Canada. The initial evaluation programme allowed for early pre-approval experience by Schulman member doctors to evaluate the commercial viability of OrthoPulse® in clinical practice.
OrthoPulse® is a clinically-proven medical device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement, thus reducing treatment time. OrthoPulse® received FDA clearance in July 2015 and is cleared by the FDA for use with both braces and clear aligners. The device is designed to be used by patients on a daily basis for a total of ten minutes, either at home or while travelling. The clinical evidence acquired to date shows a significant reduction of treatment time for patients undergoing orthodontic treatment, and feedback from patients and doctors indicates that photobiomodulation helps to reduce discomfort typically experienced by orthodontic patients.
“In the world of accelerated orthodontics, it’s comforting to find a company that under-promises and over-delivers. OrthoPulse® speeds up orthodontic treatment, reduces the discomfort associated with tooth movement and accelerates bone remodelling during the retention period. I love OrthoPulse® and my patients do too,” states Ron Redmond DDS, MS, CEO of the Schulman Study Group.
“We look forward to continuing our close relationship with Dr. Redmond and the Schulman Group,” echoes Mr. Kevin Strange, President and CEO of Biolux. “We feel that by working together with these prominent orthodontists and their focus on innovation and exceptional patient care, we can significantly expand awareness of and interest in OrthoPulse® for the benefit of patients and doctors. We expect Light Accelerated Orthodontics™ to be a game-changer for patients.”
